Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9H8H2

UPID:
DDX31_HUMAN

ALTERNATIVE NAMES:
DEAD box protein 31; Helicain

ALTERNATIVE UPACC:
Q9H8H2; Q5K6N2; Q5K6N3; Q5K6N4; Q5VZJ4; Q5VZJ9; Q96E91; Q96NY2; Q96SX5; Q9H5K6

BACKGROUND:
DEAD box protein 31, known alternatively as Helicain and Probable ATP-dependent RNA helicase DDX31, is implicated in the essential processes of ribosome biogenesis and the modulation of TP53/p53 via interaction with NPM1. This protein's function underscores its significance in cellular health and homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of DEAD box protein 31 offers a pathway to novel therapeutic avenues. Given its critical role in ribosome biogenesis and TP53/p53 regulation, targeting DDX31 in drug discovery efforts could yield innovative treatments for diseases where these pathways are disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.